None listed
Conditions
Interventions
Intervention1: Midazolam: oral midazolam will be administered at a dose of
0.75 mg/kg (strength of midazolam: 5 mg/mL) after being mixed with 0.5 mL/kg of the
selected palatability-enhancing agent (pa
Sponsors
DRDRISHADVATI MUKHERJEE
Eligibility
Inclusion criteria
Inclusion criteria: Patients classified as ASA Physical Status I or II will be included Documentation of negative behaviour will be recored, defined as scores I and II on Frankl s Behaviour Rating Scale Informed consent will be obtained from the parents or legal guardians, along with assent from the child where applicable
Exclusion criteria
Exclusion criteria: Children with a known history of allergy to benzodiazepines will be excluded Children with an altered mental status will be excluded Children with gastrointestinal disorders that could affect the absorption of midazolam will be excluded Children with anaemia (haemoglobin levels less than 10 g/dL) will be excluded Children with obesity, snoring, stridor, sleep apnea, maxillofacial malformations, a history of previous airway difficulty, gastrointestinal reflux, or acute reactive airway disease will be excluded Children with an eventful past sedation history will be excluded Dental procedures with a duration exceeding 30 minutes will be excluded from the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The study aims to comparatively evaluate the effectiveness of various palatability-enhancing agents in improving the taste acceptability and overall patient compliance of oral midazolam in paediatric dental patients, as determined by the child s preference.Timepoint: 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| not applicableTimepoint: not applicable | — |
Countries
India
Contacts
Public ContactDRDRISHADVATI MUKHERJEE
AB SHETTY MEMORIAL INSTITUTE OF DENTAL SCIENCES
Outcome results
None listed